Previous Close | 60.50 |
Open | 60.50 |
Bid | 80.50 |
Ask | 83.80 |
Strike | 690.00 |
Expire Date | 2024-05-31 |
Day's Range | 60.50 - 60.50 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.